| Drug General Information |
| Drug ID |
D08FZC
|
| Former ID |
DNC011238
|
| Drug Name |
DIETHOXYFLOURESCEIN
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C24H20O5
|
| Canonical SMILES |
CCOC1=CC2=C(C=C1)C3(C4=C(O2)C=C(C=C4)OCC)C5=CC=CC=C5C(=<br />O)O3
|
| InChI |
1S/C24H20O5/c1-3-26-15-9-11-19-21(13-15)28-22-14-16(27-4-2)10-12-20(22)24(19)18-8-6-5-7-17(18)23(25)29-24/h5-14H,3-4H2,1-2H3
|
| InChIKey |
XAPFGEPPWZRGFN-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cytochrome P450 3A4 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Steroid hormone biosynthesis
|
|
Linoleic acid metabolism
|
|
Retinol metabolism
|
|
Metabolism of xenobiotics by cytochrome P450
|
|
Drug metabolism - cytochrome P450
|
|
Drug metabolism - other enzymes
|
|
Metabolic pathways
|
|
Bile secretion
|
|
Chemical carcinogenesis
|
|
PathWhiz Pathway
|
Caffeine Metabolism
|
|
Retinol Metabolism
|
|
Reactome
|
Xenobiotics
|
|
Aflatoxin activation and detoxification
|
|
WikiPathways
|
Metapathway biotransformation
|
|
Aflatoxin B1 metabolism
|
|
Estrogen metabolism
|
|
Benzo(a)pyrene metabolism
|
|
Tamoxifen metabolism
|
|
Tryptophan metabolism
|
|
Oxidation by Cytochrome P450
|
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Farnesoid X Receptor Pathway
|
|
Vitamin D Receptor Pathway
|
|
Felbamate Metabolism
|
|
Lidocaine metabolism
|
|
Nifedipine Activity
|
|
Colchicine Metabolic Pathway
|
|
Irinotecan Pathway
|
|
Drug Induction of Bile Acid Pathway
|
|
Fatty Acid Omega Oxidation
|
|
Codeine and Morphine Metabolism
|
| References |
| REF 1 | J Med Chem. 2010 Oct 14;53(19):7129-39.Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists. |
|---|
